Andrea Maier at ARDD2025: Clinical trials in geroscience and gerotherapeutics

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the design and execution of clinical trials in geroscience, particularly the challenges of participant selection and the use of epigenetic clocks as outcomes. The speaker argues for a personalized approach, comparing it to standard medical practice (e.g., not giving insulin without measuring glucose). The argumentation is based on preliminary data from ongoing trials, which adds novelty but also limits the strength of conclusions. The speaker acknowledges limitations, such as the low AKG dose and the loss of effects over time, which enhances credibility. However, the lack of detailed statistical analysis and peer-reviewed references reduces the overall robustness.

Scientific Rigor, Source Quality, Title Accuracy

The speaker demonstrates scientific rigor by describing trial protocols, randomization, compliance checks, and responder analyses. She references a global epigenetic systematic review consortium and mentions published work on AKG, but specific citations are not provided in the talk. The title accurately reflects the content, which is a presentation of clinical trials. The talk is primarily an expert opinion based on ongoing research, with some preliminary results. The absence of detailed source citations and the reliance on unpublished data are notable weaknesses.

The title accurately reflects the content: the speaker presents clinical trials in geroscience and gerotherapeutics, focusing on participant selection, AKG trial results, adaptive trial designs, and multimodal interventions.

7/10

Presentation by a leading clinician-researcher in geroscience, describing ongoing clinical trials with preliminary results. The speaker is transparent about limitations (e.g., dosing constraints, negative secondary outcomes) and emphasizes the need for rigorous trial designs. However, the content is largely based on unpublished data and personal opinions, with limited peer-reviewed references provided.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to NUS Academy for Health Longevity and its focus on clinical research, implementation, and education.
• 05:00Discussion on participant selection in geroprotective trials, emphasizing the need to match interventions to biological age.
• 08:00Presentation of the AKG trial design, including inclusion criteria (epigenetically older) and primary outcome (epigenetic clocks).
• 12:00Recruitment results and baseline characteristics of the AKG trial participants.
• 15:00Primary outcome results: no significant difference in epigenetic clocks overall, but trends in compliant and active subgroups.
• 18:00Secondary outcomes were negative; discussion on the importance of compliance and physical activity.
• 20:00Introduction to adaptive trial design for NMN titration based on NAD+ levels, referencing the SAPI trial.
• 22:00Overview of the X-PRICE multimodal intervention study, including lifestyle, nutraceuticals, and drugs.

• No specific sources cited in the talk — The speaker mentions a global epigenetic systematic review consortium and published work on AKG, but no direct URLs or citations are provided.

• Epigenetic clocks in aging research — The use of epigenetic clocks as biomarkers of aging is consistent with the speaker's approach.

• No discordant sources identified — The talk does not directly contradict established scientific literature, but the preliminary nature of the results means they have not been peer-reviewed.